Free Trial
→ PH: Do THESE 4 things to your bank account now … (From Weiss Ratings) (Ad)tc pixel Free INDP Stock Alerts

Indaptus Therapeutics (INDP) Competitors

Indaptus Therapeutics logo
$1.22 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$1.18 -0.04 (-3.28%)
As of 05/22/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

INDP vs. LIAN, MDCX, HOTH, BLRX, and KPRX

Should you buy Indaptus Therapeutics stock or one of its competitors? MarketBeat compares Indaptus Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Indaptus Therapeutics include LianBio (LIAN), Medicus Pharma (MDCX), Hoth Therapeutics (HOTH), BioLineRx (BLRX), and Kiora Pharmaceuticals (KPRX). These companies are all part of the "pharmaceutical products" industry.

How does Indaptus Therapeutics compare to LianBio?

LianBio (NASDAQ:LIAN) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.

74.8% of LianBio shares are held by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are held by institutional investors. 7.6% of LianBio shares are held by insiders. Comparatively, 23.6% of Indaptus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

LianBio's return on equity of -33.17% beat Indaptus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
LianBioN/A -33.17% -30.19%
Indaptus Therapeutics N/A -1,030.07%-299.69%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LianBio
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Indaptus Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

LianBio is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LianBioN/AN/A-$110.29M-$0.81N/A
Indaptus TherapeuticsN/AN/A-$20.85M-$15.40N/A

LianBio has a beta of 0.23, indicating that its share price is 77% less volatile than the broader market. Comparatively, Indaptus Therapeutics has a beta of 1.37, indicating that its share price is 37% more volatile than the broader market.

In the previous week, LianBio's average media sentiment score of 0.00 equaled Indaptus Therapeutics'average media sentiment score.

Company Overall Sentiment
LianBio Neutral
Indaptus Therapeutics Neutral

Summary

Indaptus Therapeutics beats LianBio on 5 of the 9 factors compared between the two stocks.

How does Indaptus Therapeutics compare to Medicus Pharma?

Indaptus Therapeutics (NASDAQ:INDP) and Medicus Pharma (NASDAQ:MDCX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Medicus Pharma has a consensus price target of $9.00, suggesting a potential upside of 2,900.00%. Given Medicus Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Medicus Pharma is more favorable than Indaptus Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Indaptus Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Medicus Pharma
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

7.1% of Indaptus Therapeutics shares are held by institutional investors. 23.6% of Indaptus Therapeutics shares are held by company insiders. Comparatively, 8.1% of Medicus Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Indaptus Therapeutics has a beta of 1.37, meaning that its share price is 37% more volatile than the broader market. Comparatively, Medicus Pharma has a beta of -0.47, meaning that its share price is 147% less volatile than the broader market.

In the previous week, Medicus Pharma had 10 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 10 mentions for Medicus Pharma and 0 mentions for Indaptus Therapeutics. Medicus Pharma's average media sentiment score of 1.09 beat Indaptus Therapeutics' score of 0.00 indicating that Medicus Pharma is being referred to more favorably in the news media.

Company Overall Sentiment
Indaptus Therapeutics Neutral
Medicus Pharma Positive

Indaptus Therapeutics' return on equity of -1,030.07% beat Medicus Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Indaptus TherapeuticsN/A -1,030.07% -299.69%
Medicus Pharma N/A -3,137.84%-311.33%

Medicus Pharma is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Indaptus TherapeuticsN/AN/A-$20.85M-$15.40N/A
Medicus PharmaN/AN/A-$35.46M-$2.68N/A

Summary

Indaptus Therapeutics beats Medicus Pharma on 7 of the 13 factors compared between the two stocks.

How does Indaptus Therapeutics compare to Hoth Therapeutics?

Indaptus Therapeutics (NASDAQ:INDP) and Hoth Therapeutics (NASDAQ:HOTH) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability.

Hoth Therapeutics has a consensus target price of $5.00, suggesting a potential upside of 624.64%. Given Hoth Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Hoth Therapeutics is more favorable than Indaptus Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Indaptus Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Hoth Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Hoth Therapeutics is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Indaptus TherapeuticsN/AN/A-$20.85M-$15.40N/A
Hoth TherapeuticsN/AN/A-$12.47M-$0.80N/A

Hoth Therapeutics' return on equity of -165.25% beat Indaptus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Indaptus TherapeuticsN/A -1,030.07% -299.69%
Hoth Therapeutics N/A -165.25%-143.61%

Indaptus Therapeutics has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market. Comparatively, Hoth Therapeutics has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market.

In the previous week, Hoth Therapeutics had 3 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 3 mentions for Hoth Therapeutics and 0 mentions for Indaptus Therapeutics. Hoth Therapeutics' average media sentiment score of 0.57 beat Indaptus Therapeutics' score of 0.00 indicating that Hoth Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Indaptus Therapeutics Neutral
Hoth Therapeutics Positive

7.1% of Indaptus Therapeutics shares are owned by institutional investors. Comparatively, 7.1% of Hoth Therapeutics shares are owned by institutional investors. 23.6% of Indaptus Therapeutics shares are owned by company insiders. Comparatively, 6.9% of Hoth Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Hoth Therapeutics beats Indaptus Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Indaptus Therapeutics compare to BioLineRx?

BioLineRx (NASDAQ:BLRX) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

BioLineRx has higher revenue and earnings than Indaptus Therapeutics. BioLineRx is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioLineRx$1.18M11.28-$1.17M-$0.17N/A
Indaptus TherapeuticsN/AN/A-$20.85M-$15.40N/A

In the previous week, BioLineRx had 3 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 3 mentions for BioLineRx and 0 mentions for Indaptus Therapeutics. BioLineRx's average media sentiment score of 0.00 equaled Indaptus Therapeutics'average media sentiment score.

Company Overall Sentiment
BioLineRx Neutral
Indaptus Therapeutics Neutral

Indaptus Therapeutics has a net margin of 0.00% compared to BioLineRx's net margin of -99.58%. BioLineRx's return on equity of -5.61% beat Indaptus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BioLineRx-99.58% -5.61% -2.81%
Indaptus Therapeutics N/A -1,030.07%-299.69%

BioLineRx has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market. Comparatively, Indaptus Therapeutics has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioLineRx
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.67
Indaptus Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

1.6% of BioLineRx shares are owned by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are owned by institutional investors. 1.1% of BioLineRx shares are owned by company insiders. Comparatively, 23.6% of Indaptus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

BioLineRx beats Indaptus Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Indaptus Therapeutics compare to Kiora Pharmaceuticals?

Kiora Pharmaceuticals (NASDAQ:KPRX) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

Kiora Pharmaceuticals presently has a consensus price target of $10.00, indicating a potential upside of 290.63%. Given Kiora Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Kiora Pharmaceuticals is more favorable than Indaptus Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kiora Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Indaptus Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Kiora Pharmaceuticals' return on equity of -59.30% beat Indaptus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Kiora PharmaceuticalsN/A -59.30% -41.23%
Indaptus Therapeutics N/A -1,030.07%-299.69%

77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are owned by institutional investors. 0.1% of Kiora Pharmaceuticals shares are owned by insiders. Comparatively, 23.6% of Indaptus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Kiora Pharmaceuticals has a beta of -0.48, suggesting that its share price is 148% less volatile than the broader market. Comparatively, Indaptus Therapeutics has a beta of 1.37, suggesting that its share price is 37% more volatile than the broader market.

Kiora Pharmaceuticals has higher revenue and earnings than Indaptus Therapeutics. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kiora Pharmaceuticals$16.02M0.71-$10.84M-$2.71N/A
Indaptus TherapeuticsN/AN/A-$20.85M-$15.40N/A

In the previous week, Kiora Pharmaceuticals' average media sentiment score of 0.00 equaled Indaptus Therapeutics'average media sentiment score.

Company Overall Sentiment
Kiora Pharmaceuticals Neutral
Indaptus Therapeutics Neutral

Summary

Kiora Pharmaceuticals beats Indaptus Therapeutics on 9 of the 12 factors compared between the two stocks.

Get Indaptus Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for INDP and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

INDP vs. The Competition

Export
MetricIndaptus TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$138.16M$3.04B$6.46B$12.34B
Dividend YieldN/A1.97%2.76%5.28%
P/E Ratio-0.0817.7921.2125.65
Price / SalesN/A336.21554.3886.31
Price / CashN/A57.7443.4956.67
Price / Book122.005.8610.377.14
Net Income-$20.85M$74.99M$3.57B$335.98M
7 Day Performance-8.27%3.11%6.40%4.15%
1 Month Performance-63.03%-3.05%3.53%2.54%
1 Year Performance-88.19%34.38%34.04%35.06%

Indaptus Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INDP
Indaptus Therapeutics
0.3288 of 5 stars		$1.22
flat		N/A-88.2%$138.16MN/AN/A6
LIAN
LianBio
N/A$0.11
flat		N/A-69.4%$11.90MN/AN/A110
MDCX
Medicus Pharma
3.2732 of 5 stars		$0.29
+4.3%		$9.00
+3,003.4%		-95.9%$11.62MN/AN/AN/A
HOTH
Hoth Therapeutics
2.771 of 5 stars		$0.60
0.0%		$5.00
+733.5%		-19.2%$11.48MN/AN/A4
BLRX
BioLineRx
0.6982 of 5 stars		$2.75
+4.6%		N/A-16.4%$11.44M$1.18MN/A40

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:INDP) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
Trump Admin to Pump $1 Billion into this “Off-the-Radar” AI Stock
The U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...
InvestorPlace | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Gold surged 600 dollars last time this indicator peaked
The Buffett Indicator has predicted every major gold bull run this century - 2000, 2008, and 2020, when gold s...
Porter & Company | Sponsoredtc pixel
Opportunity Forming in a U.S. Supply-Chain Weak Spot?
America has a supply-chain problem with graphite - demand is climbing while dependence on foreign sources rema...
i2i Marketing Group, LLC | Sponsoredtc pixel